Occurrence of KPC-2-producing *Klebsiella pneumoniae* strains in hospital wastewater

Madam,

Carbapenem-hydrolysing β-lactamase KPC-producing isolates of *Klebsiella pneumoniae* are a major problem and concern. The first KPC-producing isolate was *K. pneumoniae* from the USA, identified in 1996, with subsequent identifications in China, Europe, Israel, Central and Brazil.1 The KPC β-lactamases, a mostly plasmid-encoded enzyme from *Klebsiella pneumoniae*, hydrolyse penicillins, cephalosporins, monobactams (aztreonam) and carbapenems, and are weakly inhibited by clavulanic acid and tazobactam.2 Genetic analysis of bla*KPC* genes indicates that their mobility and dissemination are related to a Tn3-based transposon, Tn4401, which is carried by large plasmids varying in size and structure.3,4 During the last few years, several carbapenem-hydrolysing β-lactamase KPC-producing strains have been reported in Brazil in hospitalised patients.5 This report describes the first detection of KPC-2-producing *K. pneumoniae* strains isolated in wastewater of a hospital sewage treatment plant, Rio de Janeiro, Brazil.

In August and December 2008, two KPC-2-producing isolates were recovered from effluents of a sewage treatment plant that services a hospital located in the metropolitan area of Rio de Janeiro, Brazil. The strains were collected from clarifier tank effluent (N = 1) and chlorine contact tank effluent (N = 1). The antimicrobial susceptibility profile was determined by the agar diffusion method according to CLSI guidelines.6 After species identification and antimicrobial susceptibility testing, isolates were screened for the ESBL and carbapenemase-producing phenotypes by the standard double-disc synergy test and a modified Hodge test. The minimum inhibitory concentrations were determined using Etest strips according to the manufacturer’s recommendations. Polymerase chain reaction testing was performed, as previously described, for the presence of the of *bla*KPC, *bla*TEM, *bla*SHV and *bla*CTX-M genes. Amplification products were purified and sequenced in 3730 DNA Analyser (Applied Biosystems, CA, USA), at the PDTIS-IOC DNA Sequencing Platform. Sequences were compared with those in the GenBank database.

All *K. pneumoniae* isolates showed resistance to broad-spectrum cephalosporins and carbapenems. We detected the co-resistance of piperacillin/tazobactam, ciprofloxacin and trimethoprim-sulphamethoxazole. The *K. pneumoniae* strains were of two genotypes (A, B). KPC-2-producing isolates harboured other β-lactam resistance enzymes detected by the presence of the genes *bla*KPC, *bla*TEM, *bla*SHV in all strains, whereas *bla*CTX-M was carried only by the genotype A. Sequencing of *bla*KPC revealed KPC-2 in all strains studied (Table 1).

The occurrence of KPC-2-producing *K. pneumoniae* isolates in hospital is concerning and may have a real impact on public health, principally by dissemination of these micro-organisms and their plasmids into the environment. The rapid dissemination of KPC enzymes worldwide and the consequences for treatment and infection control measures warrant a high degree of awareness and monitoring of these enzymes. The low efficacy or lack of hospital sewage treatment may contribute to the dissemination of KPC-2-producing and other multidrug-resistant bacteria from the hospital to the environment. Thus, the hospital effluent may be considered as a potential vector of contamination and spread of these emerging resistance determinants and multidrug-resistant micro-organisms. Approaches to reducing environmental microbial contamination should be considered by hospitals. However, the vast majority of hospitals in developing countries do not have sewage treatment plants, which exacerbates the problem and may have important public health implications.

**Conflict of interest statement**

None declared.

**Funding sources**

This study was supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES) and Instituto Oswaldo Cruz.

**References**


© 2010 The Hospital Infection Society. Published by Elsevier Ltd. Open access under the Elsevier OA license.

doi:10.1016/j.jhin.2010.10.008

---

**Table 1**

<table>
<thead>
<tr>
<th>Strain</th>
<th>Date</th>
<th>Genotypes</th>
<th>MIC (mg/L)</th>
<th>β-Lactamas Co-resistance*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kp 160</td>
<td>August</td>
<td>A</td>
<td>2</td>
<td>&gt;32 KPC-2; CTX-M; SXT, TZP, CIM</td>
</tr>
<tr>
<td></td>
<td>2008</td>
<td></td>
<td></td>
<td>SHV; TEM</td>
</tr>
<tr>
<td>Kp 232</td>
<td>December</td>
<td>B</td>
<td>3</td>
<td>&gt;32 KPC-2; SHV; TZP</td>
</tr>
<tr>
<td></td>
<td>2008</td>
<td></td>
<td></td>
<td>TEM</td>
</tr>
</tbody>
</table>

MIC, minimum inhibitory concentration; IPM, imipenem; MEM, meropenem; ETP, ertapenem; SXT, trimethoprim-sulphamethoxazole; TZP, piperacillin/tazobactam; CIM, ciprofloxacin.

* Intermediate was considered resistant in this analysis.